Evidence map›Paper›PMID 30373792›Full record

ArticleAntimicrobial agents and chemotherapy2019

Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides.

Yiping Wang, Rupkatha Mukhopadhyay, Sujayita Roy, Arun Kapoor, Yu-Pin Su, Susan A Charman, Gong Chen, Jianbo Wu, Xiaofang Wang, Jonathan L Vennerstrom and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yiping Wang *Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rupkatha Mukhopadhyay *Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sujayita RoyDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Arun KapoorDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yu-Pin SuDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Susan A CharmanCentre for Drug Candidate Optimization, Monash Institute of Pharmaceutical Sciences, Victoria, Australia.
Gong ChenCentre for Drug Candidate Optimization, Monash Institute of Pharmaceutical Sciences, Victoria, Australia.
Jianbo WuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Xiaofang WangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Jonathan L VennerstromDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Ravit Arav-BogerDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA rboger@mcw.edu.ORCID 0000-0002-5363-167X
Johns Hopkins University · USNebraska Medical Center · US

Funding

Optimization of Antischistosomal ChemotypesR01AI116723 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VENNERSTROM, JONATHAN L · 2015 to 2024
$6.2M
Novel Artemisinin Derivatives for Cytomegalovirus TherapyR01AI093701 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BOGER, RAVIT · 2011 to 2015
$2.0M
NIAID NIH HHS R01 AI093701NIAID NIH HHS R01 AI116723
6 · The paper itself

Abstract

Artesunate (AS), a semisynthetic artemisinin approved for malaria therapy, inhibits human cytomegalovirus (HCMV) replication

Indexed as

AnimalsAntiviral AgentsCDC2 Protein KinaseCell LineCytomegalovirusCytomegalovirus InfectionsDrug Administration ScheduleDrug Evaluation, PreclinicalDrug Resistance, ViralE2F1 Transcription FactorFemaleFibroblastsGanciclovirGene Expression RegulationHeterocyclic Compounds, 1-RingHost-Pathogen InteractionsAntiviral AgentsCDC2 Protein KinaseCDK1 protein, humanE2F1 protein, humanE2F1 Transcription FactorGanciclovirHeterocyclic Compounds, 1-RingIsoenzymesOZ418 compoundRetinoblastoma ProteinSpiro Compoundsartemisininshalf-lifehuman cytomegalovirusmouse cytomegalovirusozonidespharmacokinetics

Identifiers

PMID30373792
PMCPMC6325236
OpenAlexW2898530047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.